Allergy Immunotherapy -Pipeline Analysis, Epidemiology, and Drug Forecasting

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline and Marketed Drugs by Therapy Type

1.3.2 Pipeline and Marketed Drugs by Course of Treatment

1.3.3 Pipeline and Marketed Drugs by Causative Allergen

1.3.4 Pipeline Drugs by Phase

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By geography

2.2.1.3 By designation

2.2.2 Key Opinion Leaders (KOLs) Validation

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1 Diseases Overview

4.1.1 Overview

4.1.2 Signs/Symptoms

4.1.3 Causative Agents

4.1.3.1 Food

4.1.3.1.1 Milk

4.1.3.1.2 Peanuts

4.1.3.1.3 Eggs

4.1.3.1.4 Shellfish

4.1.3.2 Insect

4.1.3.2.1 Bee and wasp venom

4.1.3.3 Pollen

4.1.3.3.1 Grass

4.1.3.3.2 Birch

4.1.3.3.3 Ragweed

4.1.3.4 HDM

4.1.4 Types of Allergic Conditions

4.1.4.1 Allergic rhinitis (AR)

4.1.4.2 Allergic asthma

4.1.4.3 Conjunctivitis

4.1.4.4 Skin allergy

4.1.5 Diagnosis

4.2 Treatment Algorithm

4.3 Unmet Medical Needs

4.3.1 Cost of Mismanagement

4.3.2 Research on Allergy

4.3.3 Awareness of Allergic Problems

4.3.4 Unmet Need of Allergy Immunotherapy Trials

4.3.5 Need of Appropriate Biomarkers

4.4 Key Drivers

4.4.1 Increasing Prevalence of Allergic Diseases

4.4.2 Effectiveness of Immunotherapy Over Other Treatment Modalities

4.4.3 Positive Clinical Results of Pipeline Drugs

4.4.4 Advancements in Biotechnology

4.5 Barriers

4.5.1 Duration of Allergy Immunotherapy Treatment

4.5.2 Limitations of Allergy Immunotherapy

Chapter 5. Epidemiology of Allergic Diseases

5.1 7MM

5.1.1 Prevalence of Allergic Diseases

5.1.2 Prevalence of Allergic Diseases, By Gender Type

5.1.3 Prevalence of Allergic Diseases, By Age-Group

5.1.4 Prevalence of Allergic Diseases, By Specific Type

5.1.5 Prevalence of Allergic Diseases, by Causative Allergen

5.1.5.1 Prevalence of food allergy, by type

5.1.5.2 Prevalence of pollen allergy, by type

5.1.5.3 Prevalence of insect allergy, by type

5.1.6 Prevalence of Allergic Diseases, by Type

5.1.7 Diagnosed Prevalent Cases of Allergic Diseases

5.1.8 Number of Treated Cases

5.2 U.S.

5.2.1 Rationale

5.2.2 Prevalence of Allergic Diseases

5.2.3 Prevalence of Allergic Diseases, by Gender Type

5.2.4 Prevalence of Allergic Diseases, By Age-Group

5.2.5 Prevalence of Allergic Diseases, by Severity Type

5.2.6 Prevalence of Allergic Diseases, by Causative Allergen

5.2.6.1 Prevalence of food allergy, by type

5.2.6.2 Prevalence of pollen allergy, by type

5.2.6.3 Prevalence of insect allergy, by type

5.2.7 Prevalence of Allergic Diseases

5.3 EU5

5.3.1 Rationale

5.3.2 Germany

5.3.2.1 Rationale

5.3.2.2 Prevalence of allergic diseases

5.3.2.3 Prevalence of allergic diseases, by gender type

5.3.2.4 Prevalence of allergic diseases, by age-group

5.3.2.5 Prevalence of allergic diseases, by severity type

5.3.2.6 Prevalence of allergic diseases, by causative allergen

5.3.2.6.1 Prevalence of food allergy, by type

5.3.2.6.2 Prevalence of pollen allergy, by type

5.3.2.6.3 Prevalence of insect allergy, by type

5.3.2.7 Prevalence of allergic diseases by type

5.3.3 France

5.3.3.1 Rationale

5.3.3.2 Prevalence of allergic diseases

5.3.3.3 Prevalence of allergic diseases, by gender type

5.3.3.4 Prevalence of allergic diseases, by age group

5.3.3.5 Prevalence of allergic diseases, by severity type

5.3.3.6 Prevalence of allergic diseases, by causative allergen

5.3.3.6.1 Prevalence of food allergy, by type

5.3.3.6.2 Prevalence of pollen allergy, by type

5.3.3.6.3 Prevalence of insect allergy, by type

5.3.3.7 Prevalence of allergic diseases, by type

5.3.4 Italy

5.3.4.1 Rationale

5.3.4.2 Prevalence of allergic diseases

5.3.4.3 Prevalence of allergic diseases, by gender type

5.3.4.4 Prevalence of allergic diseases, by age-group

5.3.4.5 Prevalence of allergic diseases, by severity type

5.3.4.6 Prevalence of allergic diseases, by causative allergen

5.3.4.6.1 Prevalence of food allergy, by type

5.3.4.6.2 Prevalence of pollen allergy, by type

5.3.4.6.3 Prevalence of insect allergy, by type

5.3.4.7 Prevalence of allergic disease, by type

5.3.5 Spain

5.3.5.1 Rationale

5.3.5.2 Prevalence of allergic diseases

5.3.5.3 Prevalence of allergic diseases, by gender type

5.3.5.4 Prevalence of allergic diseases, by age-group

5.3.5.5 Prevalence of allergic diseases, by severity type

5.3.5.6 Prevalence of allergic diseases, by causative allergen

5.3.5.6.1 Prevalence of food allergy, by type

5.3.5.6.2 Prevalence of pollen allergy, by type

5.3.5.6.3 Prevalence of insect allergy, by type

5.3.5.7 Prevalence of allergic diseases, by type

5.3.6 U.K.

5.3.6.1 Rationale

5.3.6.2 Prevalence of allergic diseases

5.3.6.3 Prevalence of allergic diseases, by gender type

5.3.6.4 Prevalence of allergic diseases, by age-group

5.3.6.5 Prevalence of allergic diseases, by severity type

5.3.6.6 Prevalence of allergic diseases, by causative allergen

5.3.6.6.1 Prevalence of food allergy, by type

5.3.6.6.2 Prevalence of pollen allergy, by type

5.3.6.6.3 Prevalence of insect allergy, by type

5.3.6.7 Prevalence of allergic diseases, by type

5.4 Japan

5.4.1 Rationale

5.4.2 Prevalence of Allergic Diseases

5.4.3 Prevalence of Allergic Diseases, by Gender Type

5.4.4 Prevalence of Allergic Diseases, by Age-Group

5.4.5 Prevalence of Allergic Diseases, by Severity Type

5.4.6 Prevalence of Allergic Diseases, by Causative Allergen

5.4.6.1 Prevalence of food allergy, by type

5.4.6.2 Prevalence of pollen allergy, by type

5.4.6.3 Prevalence of insect allergy, by type

5.4.7 Prevalence of Allergic Diseases, by Type

Chapter 6. Allergy Immunotherapy Marketed Drugs Analysis

6.1 Marketed Drugs and Their Indication Areas

6.2 Marketed Drugs

6.2.1 SLITone

6.2.1.1 Product description

6.2.1.2 Dosage

6.2.1.3 Regulatory milestones

6.2.1.4 Clinical trials

6.2.1.5 Clinical trial results

6.2.1.6 Strategic development activities

6.2.2 XXXX

6.2.2.1 Product description

6.2.2.2 Dosage

6.2.2.3 Regulatory milestones

6.2.2.4 Clinical trials

6.2.2.5 Clinical trial results

6.2.3 XXXX

6.2.3.1 Product description

6.2.3.2 Regulatory milestones

6.2.3.3 Clinical trials

6.2.3.4 Clinical trial results

6.2.3.5 Strategic development activities

6.2.4 XXXX

6.2.4.1 Dosage

6.2.4.2 Regulatory milestones

6.2.4.3 Clinical trials and results

6.2.5 XXXX

6.2.5.1 Product description

6.2.5.2 Dosage

6.2.5.3 Regulatory milestones

6.2.5.4 Clinical trials and results

6.2.5.5 Strategic development activities

6.2.6 XXXX

6.2.6.1 Product description

6.2.6.2 Dosage

6.2.7 XXXX

6.2.7.1 Dosage and strength

6.2.7.2 Regulatory milestones

6.2.7.3 Clinical trial results

6.2.7.4 Strategic development activities

6.2.8 XXXX

6.2.8.1 XXXX

6.2.8.2 Dosage

6.2.8.3 XXXX

6.2.8.4 Dosage

6.2.8.5 XXXX

6.2.8.6 Dosage

6.2.8.7 Strategic development activities

6.2.9 XXXX

6.2.9.1 Dosage

6.2.9.2 Clinical trials

6.2.9.3 Clinical trials results

6.2.9.4 Regulatory milestones

6.2.10 XXXX

6.2.10.1 Dosage

6.2.10.2 Clinical trials

6.2.10.3 Strategic development activities

6.2.11 XXXX

6.2.11.1 Dosage

6.2.11.2 Clinical trials

6.2.11.3 Clinical trials results

6.2.11.4 Strategic development activities

6.2.12 XXXX

6.2.12.1 Dosage

6.2.12.2 Clinical trials

6.2.12.3 Clinical trials results

6.2.12.4 Strategic development activities

6.2.13 XXXX

6.2.13.1 Dosage

6.2.13.2 Clinical trials

6.2.13.3 Clinical trials results

6.2.13.4 Strategic development activities

6.2.14 XXXX

6.2.14.1 Dosage

6.2.14.2 Clinical trials

6.2.14.3 Strategic development activities

6.2.15 XXXX

6.2.15.1 Dosage

6.2.15.2 Strategic development activities

6.2.16 XXXX

6.2.16.1 Clinical trials

6.2.16.2 Clinical study result

6.2.16.3 Strategic development activities

Chapter 7. Allergy Immunotherapy Pipeline Analysis

7.1 Pre-Registration

7.1.1 Palforzia

7.1.1.1 Clinical trials

7.1.1.2 Clinical trial results

7.1.1.3 Strategic development activities

7.1.1.4 Designations

7.1.1.5 Name change

7.1.1.6 Financing

7.1.1.7 Technology

7.1.2 XXXX

7.1.2.1 Clinical trials

7.1.2.2 Clinical trial results

7.1.2.3 Strategic development activities

7.1.2.4 Designation

7.1.2.5 Patent

7.1.2.6 Grant

7.1.2.7 IND acceptance

7.2 Phase III

7.2.1 Xolair

7.2.1.1 Clinical trials

7.2.1.2 Designation

7.2.2 XXXX

7.2.2.1 Clinical trials

7.2.2.2 Clinical trial results

7.2.2.3 Strategic development activities

7.2.3 XXXX

7.2.3.1 XXXX XXXX XXXX

7.2.3.1.1 Clinical trials

7.2.3.1.2 Clinical trials results

7.2.3.2 XXXX XXXX XXXX

7.2.3.2.1 Clinical trials

7.2.3.3 Clinical trials results

7.2.3.4 XXXX XXXX XXXX

7.2.3.4.1 Clinical trials

7.2.3.4.2 Clinical trials results

7.3 Phase II

7.3.1 AllerT

7.3.1.1 Clinical trials

7.3.1.2 Clinical trial results

7.3.2 XXXX

7.3.2.1 Clinical trials

7.3.2.2 Clinical trial results

7.3.3 XXXX

7.3.3.1 Clinical trials

7.3.3.2 Strategic development activities

7.3.4 XXXX

7.3.4.1 Clinical trials

7.3.5 XXXX

7.3.5.1 Clinical trials

7.3.6 XXXX

7.3.6.1 Clinical trials

7.3.6.2 Strategic development activities

7.3.7 XXXX

7.3.7.1 Clinical trials

7.3.7.2 Strategic development activities

7.4 Phase I

7.4.1 INP20

7.4.1.1 Clinical trials

7.4.1.2 Financing

7.4.2 XXXX

7.4.2.1 Clinical trials

7.4.2.2 Financing

7.4.3 XXXX

7.4.3.1 Clinical trials

7.4.3.2 Designations

7.4.3.3 Strategic development activities

Chapter 8. Allergy Immunotherapy Market Size Analysis

8.1 7MM

8.1.1 Allergy Immunotherapy Market, by Causative Allergen

8.1.2 Allergy Immunotherapy Market, by Therapy Type

8.1.3 Allergy Immunotherapy Market, by Disease Type

8.1.4 Allergy Immunotherapy Market, by Course of Treatment

8.1.5 Allergy Immunotherapy Market Share Split in 7MM

Chapter 9. Regulatory Framework for Drug Approval

9.1 U.S.

9.2 Europe

9.2.1 Centralized Procedure

9.2.2 Mutual Recognition Procedure

9.2.3 Decentralized Procedure

9.2.4 Nationalized Procedure

9.3 Japan

Chapter 10. Competitive Landscape

10.1 Key Cross Competition

10.2 Market Share of Late-Stage Immunotherapies in 2030

10.3 Brand Share Analysis

10.3.1 ALK-Abelló A/S

10.3.2 Allergy Therapeutics PLC

10.3.3 Stallergenes Greer Ltd

Chapter 11. Company Profiles

11.1 ALK-Abelló A/S

11.1.1 Business Overview

11.1.2 Product and Service Offerings

11.1.3 Key Financial Summary

11.2 Xxxx

11.2.1 Business Overview

11.2.2 Product and Service Offerings

11.2.3 Key Financial Summary

11.3 Aimmune Therapeutics Inc.

11.3.1 Business Overview

11.3.2 Product and Service Offerings

11.4 Xxxx

11.4.1 Business Overview

11.4.2 Product and Service Offerings

11.4.3 Key Financial Summary

11.5 Xxxx.

11.5.1 Business Overview

11.5.2 Product Offerings

11.6 Xxxx.

11.6.1 Business Overview

11.6.2 Product and Service Offerings

11.6.3 Key Financial Summary

11.7 Xxxx

11.7.1 Business Overview

11.7.2 Product and Service Offerings

11.7.3 Key Financial Summary

11.8 Xxxx

11.8.1 Business Overview

11.8.2 Product and Service Offerings

11.9 Xxxx

11.9.1 Business Overview

11.9.2 Product and Service Offerings

11.10 Xxxx.

11.10.1 Business Overview

11.10.2 Product and Service Offerings

11.11 Xxxx

11.11.1 Business Overview

11.11.2 Product and Service Offerings

11.12 F. Hoffmann-La Roche Ltd. (Roche)

11.12.1 Business Overview

11.12.2 Product and Service Offerings

11.12.3 Key Financial Summary

11.13 Xxxx

11.13.1 Business Overview

11.13.2 Product and Service Offerings

11.13.3 Key Financial Summary

11.14 Xxxx.

11.14.1 Business Overview

11.14.2 Product and Service Offerings

11.14.3 Key Financial Summary

Chapter 12. Appendix

12.1 Recently Organized/Held Seminars and Conferences

12.2 Upcoming Conferences

12.3 Sources & References

12.4 Abbreviations

12.5 Related Reports

 

LIST OF TABLES

 

TABLE 1 ALLERGIC DISEASES

TABLE 2 CLASSIFICATION OF FOOD ALLERGIES

TABLE 3 TYPES OF DISORDERS OF ALLERGIC CONJUNCTIVITIS

TABLE 4 GRADING CRITERIA BY WHEAL SIZE FOR ALLERGY SKIN TESTING

TABLE 5 EPIDEMIOLOGY OF ALLERGIC DISEASES IN 7MM (2014–2019)

TABLE 6 EPIDEMIOLOGY OF ALLERGIC DISEASES IN 7MM (2020–2030)

TABLE 7 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY GENDER TYPE (2014–2019)

TABLE 8 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY GENDER TYPE (2020–2030)

TABLE 9 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY AGE-GROUP (2014–2019E)

TABLE 10 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY AGE-GROUP (2020–2030)

TABLE 11 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY SEVERITY TYPE (2014–2019)

TABLE 12 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY SEVERITY TYPE (2020–2030)

TABLE 13 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY CAUSATIVE ALLERGEN (2014–2019)

TABLE 14 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY CAUSATIVE ALLERGEN (2020–2030)

TABLE 15 PREVALENCE OF FOOD ALLERGY IN 7MM, BY TYPE (2014–2019)

TABLE 16 PREVALENCE OF FOOD ALLERGY IN 7MM, BY TYPE (2020–2030)

TABLE 17 PREVALENCE OF POLLEN ALLERGY IN 7MM, BY TYPE (2014–2019)

TABLE 18 PREVALENCE OF POLLEN ALLERGY IN 7MM, BY TYPE (2020–2030)

TABLE 19 PREVALENCE OF INSECT ALLERGY IN 7MM, BY TYPE (2014–2019)

TABLE 20 PREVALENCE OF INSECT ALLERGY IN 7MM, BY TYPE (2020–2030)

TABLE 21 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY TYPE (2014–2019)

TABLE 22 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY TYPE (2020–2030)

TABLE 23 DIAGNOSED PREVALENT CASES OF ALLERGIC DISEASES IN 7MM (2014–2019)

TABLE 24 DIAGNOSED PREVALENT CASES OF ALLERGIC DISEASES IN 7MM (2020–2030)

TABLE 25 NUMBER OF TREATED CASES IN 7MM (2014–2019)

TABLE 26 NUMBER OF TREATED CASES IN THE 7MM (2020–2030)

TABLE 27 EPIDEMIOLOGY OF ALLERGIC DISEASES IN THE U.S. (2014–2019)

TABLE 28 EPIDEMIOLOGY OF ALLERGIC DISEASES IN THE U.S (2020–2030)

TABLE 29 PREVALENCE OF ALLERGIC DISEASES IN THE U.S., BY GENDER TYPE (2014–2019)

TABLE 30 PREVALENCE OF ALLERGIC DISEASES IN THE U.S., BY GENDER TYPE (2020–2030)

TABLE 31 PREVALENCE OF ALLERGIC DISEASES IN THE U.S., BY AGE-GROUP (2014–2019)

TABLE 32 PREVALENCE OF ALLERGIC DISEASES IN THE U.S., BY AGE-GROUP (2020–2030)

TABLE 33 PREVALENCE OF ALLERGIC DISEASES IN THE U.S., BY SEVERITY TYPE (2014–2019E)

TABLE 34 PREVALENCE OF ALLERGIC DISEASES IN THE U.S., BY SEVERITY TYPE (2020–2030)

TABLE 35 PREVALENCE OF ALLERGIC DISEASES IN THE U.S., BY CAUSATIVE ALLERGEN (2014–2019)

TABLE 36 PREVALENCE OF ALLERGIC DISEASES BY CAUSATIVE ALLERGEN IN THE U.S. (2020–2030)

TABLE 37 PREVALENCE OF FOOD ALLERGY IN THE U.S., BY TYPE (2014–2019)

TABLE 38 PREVALENCE OF FOOD ALLERGY IN THE U.S., BY TYPE (2020–2030)

TABLE 39 PREVALENCE OF POLLEN ALLERGY IN THE U.S., BY TYPE (2014–2019)

TABLE 40 PREVALENCE OF POLLEN ALLERGY IN THE U.S. (2020–2030)

TABLE 41 PREVALENCE OF INSECT ALLERGY IN THE U.S., BY TYPE (2014–2019)

TABLE 42 PREVALENCE OF INSECT ALLERGY IN THE U.S., BY TYPE (2020–2030)

TABLE 43 PREVALENCE OF ALLERGIC DISEASES IN THE U.S., BY TYPE (2014–2019)

TABLE 44 TYPE-SPECIFIC PREVALENCE OF ALLERGIC DISEASES IN THE U.S. (2020–2030)

TABLE 45 PREVALENCE OF ALLERGIC DISEASES IN EU5 (2014–2019)

TABLE 46 PREVALENCE OF ALLERGIC DISEASES IN EU5 (2020–2030)

TABLE 47 EPIDEMIOLOGY OF ALLERGIC DISEASES IN GERMANY (2014–2019)

TABLE 48 EPIDEMIOLOGY OF ALLERGIC DISEASES IN GERMANY (2026–2030)

TABLE 49 PREVALENCE OF ALLERGIC DISEASES IN GERMANY, BY GENDER TYPE (2014–2019)

TABLE 50 PREVALENCE OF ALLERGIC DISEASES IN GERMANY, BY GENDER TYPE (2020–2030)

TABLE 51 AGE-GROUP SPECIFIC PREVALENCE OF ALLERGIC DISEASES IN GERMANY (2014–2019)

TABLE 52 AGE-GROUP SPECIFIC PREVALENCE OF ALLERGIC DISEASES IN GERMANY (2020–2030)

TABLE 53 PREVALENCE OF ALLERGIC DISEASES IN GERMANY, BY SEVERITY TYPE (2014–2019)

TABLE 54 PREVALENCE OF ALLERGIC DISEASES IN GERMANY, BY SEVERITY TYPE (2020–2030)

TABLE 55 PREVALENCE OF ALLERGIC DISEASES IN GERMANY BY CAUSATIVE ALLERGEN (2014–2019)

TABLE 56 PREVALENCE OF ALLERGIC DISEASES IN GERMANY BY CAUSATIVE ALLERGEN (2020–2030)

TABLE 57 PREVALENCE OF FOOD ALLERGY IN GERMANY, BY TYPE (2014–2019)

TABLE 58 PREVALENCE OF FOOD ALLERGY IN GERMANY, BY TYPE (2020–2030)

TABLE 59 PREVALENCE OF POLLEN ALLERGY IN GERMANY, BY TYPE (2014–2019)

TABLE 60 PREVALENCE OF POLLEN ALLERGY IN GERMANY, BY TYPE (2020–2030)

TABLE 61 PREVALENCE OF INSECT ALLERGY IN GERMANY, BY TYPE (2014–2019)

TABLE 62 PREVALENCE OF INSECT ALLERGY IN GERMANY, BY TYPE (2020–2030)

TABLE 63 PREVALENCE OF ALLERGIC DISEASES IN GERMANY, BY TYPE (2014–2019)

TABLE 64 PREVALENCE OF ALLERGIC DISEASES IN GERMANY, BY TYPE (2020–2030)

TABLE 65 EPIDEMIOLOGY OF ALLERGIC DISEASES IN FRANCE (2014–2019)

TABLE 66 EPIDEMIOLOGY OF ALLERGIC DISEASES IN FRANCE (2020–2030)

TABLE 67 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY GENDER TYPE (2014–2019)

TABLE 68 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY GENDER TYPE (2020–2030)

TABLE 69 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY AGE-GROUP (2014–2019)

TABLE 70 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY AGE-GROUP (2020–2030)

TABLE 71 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY SEVERITY TYPE (2014–2019)

TABLE 72 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY SEVERITY TYPE (2020–2030)

TABLE 73 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY CAUSATIVE ALLERGEN (2014–2019)

TABLE 74 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY CAUSATIVE ALLERGEN (2020–2030)

TABLE 75 PREVALENCE OF FOOD ALLERGY IN FRANCE, BY TYPE (2014–2019)

TABLE 76 PREVALENCE OF FOOD ALLERGY IN FRANCE, BY TYPE (2020–2030)

TABLE 77 PREVALENCE OF POLLEN ALLERGY IN FRANCE, BY TYPE (2014–2019)

TABLE 78 PREVALENCE OF POLLEN ALLERGY IN FRANCE, BY TYPE (2020–2030)

TABLE 79 PREVALENCE OF INSECT ALLERGY IN FRANCE, BY TYPE (2014–2019)

TABLE 80 PREVALENCE OF INSECT ALLERGY IN FRANCE, BY TYPE (2020–2030)

TABLE 81 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY TYPE (2014–2019)

TABLE 82 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY TYPE (2020–2030)

TABLE 83 EPIDEMIOLOGY OF ALLERGIC DISEASES IN ITALY (2014–2019)

TABLE 84 EPIDEMIOLOGY OF ALLERGIC DISEASES IN ITALY (2020–2030)

TABLE 85 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY GENDER TYPE (2014–2019)

TABLE 86 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY GENDER TYPE (2020–2030)

TABLE 87 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY AGE-GROUP (2014–2019)

TABLE 88 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY AGE-GROUP (2020–2030)

TABLE 89 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY SEVERITY TYPE (2014–2019)

TABLE 90 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY SEVERITY TYPE (2020–2030)

TABLE 91 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY CAUSATIVE ALLERGEN (2014–2019)

TABLE 92 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY CAUSATIVE ALLERGEN (2020–2030)

TABLE 93 PREVALENCE OF FOOD ALLERGY IN ITALY, BY TYPE (2014–2019E)

TABLE 94 PREVALENCE OF FOOD ALLERGY IN ITALY, BY TYPE (2020–2030)

TABLE 95 PREVALENCE OF POLLEN ALLERGY IN ITALY, BY TYPE (2014–2019)

TABLE 96 PREVALENCE OF POLLEN ALLERGY IN ITALY, BY TYPE (2020–2030)

TABLE 97 PREVALENCE OF INSECT ALLERGY IN ITALY, BY TYPE (2014–2019)

TABLE 98 PREVALENCE OF INSECT ALLERGY IN ITALY, BY TYPE (2020–2030)

TABLE 99 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY TYPE (2014–2019)

TABLE 100 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY TYPE (2020–2030)

TABLE 101 EPIDEMIOLOGY OF ALLERGIC DISEASES IN SPAIN (2014–2019)

TABLE 102 EPIDEMIOLOGY OF ALLERGIC DISEASES IN SPAIN (2020–2030)

TABLE 103 PREVALENCE OF ALLERGIC DISEASES IN SPAIN, BY GENDER TYPE (2014–2019)

TABLE 104 PREVALENCE OF ALLERGIC DISEASES IN SPAIN, BY GENDER TYPE (2020–2030)

TABLE 105 PREVALENCE OF ALLERGIC DISEASES IN SPAIN, BY AGE-GROUP (2014–2019)

TABLE 106 PREVALENCE OF ALLERGIC DISEASES IN SPAIN, BY AGE-GROUP (2020–2030)

TABLE 107 PREVALENCE OF ALLERGIC DISEASES IN SPAIN, BY SEVERITY TYPE (2014–2019)

TABLE 108 PREVALENCE OF ALLERGIC DISEASES IN SPAIN, BY SEVERITY TYPE (2020–2030)

TABLE 109 PREVALENCE OF ALLERGIC DISEASES IN SPAIN, BY CAUSATIVE ALLERGEN (2014–2019)

TABLE 110 PREVALENCE OF ALLERGIC DISEASES BY CAUSATIVE ALLERGEN IN SPAIN (2020–2030)

TABLE 111 PREVALENCE OF FOOD ALLERGY IN SPAIN, BY TYPE (2014–2019)

TABLE 112 PREVALENCE OF FOOD ALLERGY IN SPAIN, BY TYPE (2020–2030)

TABLE 113 PREVALENCE OF POLLEN ALLERGY IN SPAIN, BY TYPE (2014–2019)

TABLE 114 PREVALENCE OF POLLEN ALLERGY IN SPAIN, BY TYPE (2020–2030)

TABLE 115 PREVALENCE OF INSECT ALLERGY IN SPAIN, BY TYPE (2014–2019)

TABLE 116 PREVALENCE OF INSECT ALLERGY IN SPAIN, BY TYPE (2020–2030)

TABLE 117 PREVALENCE OF ALLERGIC DISEASES IN SPAIN, BY TYPE (2014–2019E)

TABLE 118 PREVALENCE OF ALLERGIC DISEASES IN SPAIN, BY TYPE (2020–2030)

TABLE 119 EPIDEMIOLOGY OF ALLERGIC DISEASES IN THE U.K. (2014–2019)

TABLE 120 EPIDEMIOLOGY OF ALLERGIC DISEASES IN THE U.K. (2020–2030)

TABLE 121 PREVALENCE OF ALLERGIC DISEASES IN THE U.K., BY GENDER TYPE (2014–2019)

TABLE 122 PREVALENCE OF ALLERGIC DISEASES IN THE U.K., BY GENDER TYPE (2026–2030)

TABLE 123 PREVALENCE OF ALLERGIC DISEASES IN THE U.K., BY AGE-GROUP (2014–2019)

TABLE 124 AGE-GROUP SPECIFIC PREVALENCE OF ALLERGIC DISEASES IN THE U.K. (2020–2030)

TABLE 125 PREVALENCE OF ALLERGIC DISEASES IN THE U.K., BY SEVERITY TYPE (2014–2019)

TABLE 126 SEVERITY-SPECIFIC PREVALENCE OF ALLERGIC DISEASES IN THE U.K. (2020–2030)

TABLE 127 PREVALENCE OF ALLERGIC DISEASES BY CAUSATIVE ALLERGEN IN THE U.K. (2014–2019)

TABLE 128 PREVALENCE OF ALLERGIC DISEASES BY CAUSATIVE ALLERGEN IN THE U.K. (2020–2030)

TABLE 129 PREVALENCE OF FOOD ALLERGY IN THE U.K., BY TYPE (2014–2019)

TABLE 130 PREVALENCE OF FOOD ALLERGY IN THE U.K., BY TYPE (2020–2030)

TABLE 131 PREVALENCE OF POLLEN ALLERGY IN THE U.K., BY TYPE (2014–2019E)

TABLE 132 PREVALENCE OF POLLEN ALLERGY IN THE U.K., BY TYPE (2020–2030)

TABLE 133 PREVALENCE OF INSECT ALLERGY IN THE U.K., BY TYPE (2014–2019E)

TABLE 134 PREVALENCE OF INSECT ALLERGY IN THE U.K. (2020–2030)

TABLE 135 TYPE-SPECIFIC PREVALENCE OF ALLERGIC DISEASES IN THE U.K. (2014–2019E)

TABLE 136 PREVALENCE OF ALLERGIC DISEASES IN THE U.K., BY TYPE (2020–2030)

TABLE 137 EPIDEMIOLOGY OF ALLERGIC DISEASES IN JAPAN (2014–2019)

TABLE 138 EPIDEMIOLOGY OF ALLERGIC DISEASES IN JAPAN (2020–2030)

TABLE 139 PREVALENCE OF ALLERGIC DISEASES IN JAPAN, BY GENDER TYPE (2014–2019)

TABLE 140 PREVALENCE OF ALLERGIC DISEASES IN JAPAN, BY GENDER TYPE (2020–2030)

TABLE 141 PREVALENCE OF ALLERGIC DISEASES IN JAPAN, BY AGE-GROUP (2014–2019E)

TABLE 142 PREVALENCE OF ALLERGIC DISEASES IN JAPAN, BY AGE-GROUP (2020–2030)

TABLE 143 PREVALENCE OF ALLERGIC DISEASES IN JAPAN, BY SEVERITY TYPE (2014–2019)

TABLE 144 PREVALENCE OF ALLERGIC DISEASES IN JAPAN, BY SEVERITY TYPE (2020–2030)

TABLE 145 PREVALENCE OF ALLERGIC DISEASES IN JAPAN, BY CAUSATIVE ALLERGEN (2014–2019)

TABLE 146 PREVALENCE OF ALLERGIC DISEASES BY CAUSATIVE ALLERGEN IN JAPAN (2020–2030)

TABLE 147 PREVALENCE OF FOOD ALLERGY IN JAPAN, BY TYPE (2014–2019)

TABLE 148 PREVALENCE OF FOOD ALLERGY IN JAPAN, BY TYPE (2020–2030)

TABLE 149 PREVALENCE OF POLLEN ALLERGY IN JAPAN, BY TYPE (2014–2019)

TABLE 150 PREVALENCE OF POLLEN ALLERGY IN JAPAN, BY TYPE (2020–2030)

TABLE 151 PREVALENCE OF INSECT ALLERGY IN JAPAN, BY TYPE (2014–2019)

TABLE 152 PREVALENCE OF INSECT ALLERGY IN JAPAN, BY TYPE (2020–2030)

TABLE 153 PREVALENCE OF ALLERGIC DISEASES IN JAPAN, BY TYPE (2014–2019)

TABLE 154 PREVALENCE OF ALLERGIC DISEASES IN JAPAN, BY TYPE (2020–2030)

TABLE 155 MARKETED DRUGS AND THEIR INDICATION AREAS

TABLE 156 DESCRIPTION OF SLITONE

TABLE 157 CLINICAL TRIALS OF SLITONE

TABLE 158 DESCRIPTION OF XXXX

TABLE 159 CLINICAL TRIALS OF XXXX

TABLE 160 DESCRIPTION OF XXXX

TABLE 161 CLINICAL TRIALS OF XXXX

TABLE 162 DESCRIPTION OF XXXX

TABLE 163 CLINICAL TRIALS OF XXXX

TABLE 164 DESCRIPTION OF XXXX

TABLE 165 DESCRIPTION OF XXXX

TABLE 166 DESCRIPTION OF XXXX

TABLE 167 CLINICAL TRIALS OF XXXX

TABLE 168 DESCRIPTION OF XXXX

TABLE 169 DOSING SCHEDULE OF XXXX FOR AVERAGE PATIENTS

TABLE 170 DOSING SCHEDULE OF XXXX FOR HIGHLY SENSITISED PATIENTS

TABLE 171 DESCRIPTION OF XXXX

TABLE 172 DOSING SCHEDULE OF XXXX

TABLE 173 DESCRIPTION OF XXXX

TABLE 174 DOSING SCHEDULE OF XXXX

TABLE 175 DESCRIPTION OF XXXX

TABLE 176 CLINICAL TRIALS OF XXXX

TABLE 177 DESCRIPTION OF XXXX

TABLE 178 DOSING SCHEDULE OF XXXX

TABLE 179 CLINICAL TRIALS OF XXXX

TABLE 180 DESCRIPTION OF XXXX

TABLE 181 CLINICAL TRIALS OF XXXX

TABLE 182 DESCRIPTION OF XXXX

TABLE 183 CLINICAL TRIALS OF XXXX

TABLE 184 DESCRIPTION OF XXXX

TABLE 185 CLINICAL TRIALS OF XXXX

TABLE 186 DESCRIPTION OF XXXX

TABLE 187 DOSING SCHEDULE OF XXXX

TABLE 188 CLINICAL TRIALS OF XXXX

TABLE 189 DESCRIPTION OF XXXX

TABLE 190 DOSING SCHEDULE OF XXXX

TABLE 191 DESCRIPTION OF XXXX

TABLE 192 CLINICAL TRIALS OF XXXX

TABLE 193 DESCRIPTION OF PALFORZIA

TABLE 194 CLINICAL TRIALS OF PALFORZIA

TABLE 195 DESCRIPTION OF XXXX

TABLE 196 CLINICAL TRIALS OF XXXX

TABLE 197 DESCRIPTION OF XOLAIR

TABLE 198 CLINICAL TRIALS OF XOLAIR

TABLE 199 DESCRIPTION OF XXXX

TABLE 200 CLINICAL TRIALS OF XXXX

TABLE 201 DESCRIPTION OF XXXX

TABLE 202 CLINICAL TRIALS OF XXXX

TABLE 203 CLINICAL TRIALS OF XXXX

TABLE 204 CLINICAL TRIALS OF XXXX

TABLE 205 DESCRIPTION OF ALLERT

TABLE 206 CLINICAL TRIALS OF ALLERT

TABLE 207 DESCRIPTION OF XXXX

TABLE 208 CLINICAL TRIALS OF XXXX

TABLE 209 DESCRIPTION OF XXXX

TABLE 210 CLINICAL TRIALS OF XXXX

TABLE 211 DESCRIPTION OF XXXX

TABLE 212 CLINICAL TRIALS OF XXXX

TABLE 213 DESCRIPTION OF XXXX

TABLE 214 CLINICAL TRIALS OF XXXX

TABLE 215 DESCRIPTION OF XXXX

TABLE 216 CLINICAL TRIALS OF XXXX

TABLE 217 DESCRIPTION OF XXXX

TABLE 218 CLINICAL TRIALS OF XXXX

TABLE 219 CLINICAL TRIALS OF INP20

TABLE 220 DESCRIPTION OF XXXX

TABLE 221 CLINICAL TRIALS OF XXXX

TABLE 222 DESCRIPTION OF XXXX

TABLE 223 CLINICAL TRIALS OF XXXX

TABLE 224 ALLERGY IMMUNOTHERAPY MARKET, BY CAUSATIVE ALLERGEN IN 7MM, $M (2017–2024)

TABLE 225 ALLERGY IMMUNOTHERAPY MARKET, BY CAUSATIVE ALLERGEN IN 7MM, $M (2025–2030)

TABLE 226 ALLERGY IMMUNOTHERAPY MARKET, BY THERAPY TYPE IN 7MM, $M (2017–2024)

TABLE 227 ALLERGY IMMUNOTHERAPY MARKET, BY THERAPY TYPE IN 7MM, $M (2025–2030)

TABLE 228 ALLERGY IMMUNOTHERAPY MARKET, BY DISEASE TYPE IN 7MM, $M (2017–2024)

TABLE 229 ALLERGY IMMUNOTHERAPY MARKET, BY DISEASE TYPE IN 7MM, $M (2025–2030)

TABLE 230 ALLERGY IMMUNOTHERAPY MARKET, BY COURSE OF TREATMENT IN 7MM, $M (2017–2024)

TABLE 231 ALLERGY IMMUNOTHERAPY MARKET, BY COURSE OF TREATMENT IN 7MM, $M (2025–2030)

TABLE 232 KEY CROSS COMPETITION OF PALFORZIA, VIASKIN, AND XOLAIR

TABLE 233 KEY CROSS COMPETITION OF GP-ASIT+, HDM-ASIT+, AND AR201

TABLE 234 KEY CROSS COMPETITION OF POLLINEX QUATTRO, MG56-I, AND MM09

TABLE 235 KEY CROSS COMPETITION OF BM32, DUPILUMAB, AND ALLERT

TABLE 236 ALK-ABELLÓ A/S – AT A GLANCE

TABLE 237 ALK-ABELLÓ A/S – PIPELINE PRODUCTS

TABLE 238 ALK-ABELLÓ A/S – KEY FINANCIAL SUMMARY

TABLE 239 XXXX – AT A GLANCE

TABLE 240 XXXX – KEY FINANCIAL SUMMARY

TABLE 241 AIMMUNE THERAPEUTICS INC. – AT A GLANCE

TABLE 242 XXXX – AT A GLANCE

TABLE 243 XXXX – PIPELINE PRODUCTS

TABLE 244 XXXX – KEY FINANCIAL SUMMARY

TABLE 245 XXXX – AT A GLANCE

TABLE 246 XXXX – PIPELINE PRODUCTS

TABLE 247 XXXX – AT A GLANCE

TABLE 248 XXXX – KEY FINANCIAL SUMMARY

TABLE 249 XXXX – AT A GLANCE

TABLE 250 XXXX – KEY FINANCIAL SUMMARY

TABLE 251 XXXX AT A GLANCE

TABLE 252 XXXX AT A GLANCE

TABLE 253 XXXX – AT A GLANCE

TABLE 254 XXXX – AT A GLANCE

TABLE 255 F. HOFFMANN-LA ROCHE LTD. – AT A GLANCE

TABLE 256 F. HOFFMANN-LA ROCHE LTD. – KEY FINANCIAL SUMMARY

TABLE 257 XXXX – AT A GLANCE

TABLE 258 XXXX - PIPELINE PRODUCTS

TABLE 1 XXXX – KEY FINANCIAL SUMMARY

TABLE 259 XXXX – AT A GLANCE

TABLE 260 XXXX – KEY FINANCIAL SUMMARY

TABLE 261 RECENTLY ORGANIZED SEMINARS AND CONFERENCES

TABLE 262 UPCOMING SEMINARS AND CONFERENCES

TABLE 263 SOURCES & REFERENCES

TABLE 264 ABBREVIATIONS

 

LIST OF FIGURES

 

FIG 1 RESEARCH METHODOLOGY

FIG 2 BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY GEOGRAPHY

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION

FIG 5 ALLERGY IMMUNOTHERAPY – UNMET NEEDS

FIG 6 NUMBER OF PREVALENT CASES IN 7MM (2018 & 2030)

FIG 7 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY GENDER TYPE (2014–2030)

FIG 8 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY AGE-GROUP (2014–2030)

FIG 9 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY SPECIFIC TYPE (2014–2030)

FIG 10 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY CAUSATIVE ALLERGEN (2014–2030)

FIG 11 PREVALENCE OF FOOD ALLERGY IN 7MM, BY TYPE (2014–2030)

FIG 12 PREVALENCE OF POLLEN ALLERGY IN 7MM, BY TYPE (2014–2030)

FIG 13 PREVALENCE OF INSECT ALLERGY IN 7MM, BY TYPE (2014–2030)

FIG 14 PREVALENCE OF ALLERGIC DISEASES IN 7MM, BY TYPE (2014–2030)

FIG 15 DIAGNOSED PREVALENT CASES OF ALLERGIC DISEASES IN 7MM (2014–2030)

FIG 16 NUMBER OF TREATED CASES IN 7MM (2014–2030)

FIG 17 PREVALENCE OF ALLERGIC DISEASES IN THE U.S., BY GENDER TYPE (2014–2030)

FIG 18 PREVALENCE OF ALLERGIC DISEASES IN THE U.S., BY AGE-GROUP (2014–2030)

FIG 19 PREVALENCE OF ALLERGIC DISEASES IN THE U.S., BY SEVERITY TYPE (2014–2030)

FIG 20 PREVALENCE OF ALLERGIC DISEASES IN THE U.S., BY CAUSATIVE ALLERGEN (2014–2030)

FIG 21 PREVALENCE OF FOOD ALLERGY IN THE U.S., BY TYPE (2014–2030)

FIG 22 PREVALENCE OF POLLEN ALLERGY IN THE U.S., BY TYPE (2014–2030)

FIG 23 PREVALENCE OF INSECT ALLERGY IN THE U.S., BY TYPE (2014–2030)

FIG 24 PREVALENCE OF ALLERGIC DISEASES IN THE U.S., BY TYPE (2014–2030)

FIG 25 PREVALENCE OF ALLERGIC DISEASES IN EU5 (2014–2030)

FIG 26 PREVALENCE OF ALLERGIC DISEASES IN GERMANY, BY GENDER TYPE (2014–2030)

FIG 27 AGE-GROUP SPECIFIC PREVALENCE OF ALLERGIC DISEASES IN GERMANY (2014–2030)

FIG 28 PREVALENCE OF ALLERGIC DISEASES IN GERMANY, BY SEVERITY TYPE (2014–2030)

FIG 29 PREVALENCE OF ALLERGIC DISEASES IN GERMANY, BY CAUSATIVE ALLERGEN (2014–2030)

FIG 30 PREVALENCE OF FOOD ALLERGY IN GERMANY, BY TYPE (2014–2030)

FIG 31 PREVALENCE OF POLLEN ALLERGY IN GERMANY, BY TYPE (2014–2030)

FIG 32 PREVALENCE OF INSECT ALLERGY IN GERMANY, BY TYPE (2014–2030)

FIG 33 PREVALENCE OF ALLERGIC DISEASES IN GERMANY, BY TYPE (2014–2030)

FIG 34 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY GENDER TYPE (2014–2030)

FIG 35 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY AGE GROUP (2014–2030)

FIG 36 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY SEVERITY TYPE (2014–2030)

FIG 37 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY CAUSATIVE ALLERGEN (2014–2030)

FIG 38 PREVALENCE OF FOOD ALLERGY IN FRANCE, BY TYPE (2014–2030)

FIG 39 PREVALENCE OF POLLEN ALLERGY IN FRANCE, BY TYPE (2014–2030)

FIG 40 PREVALENCE OF INSECT ALLERGY IN FRANCE, BY TYPE (2014–2030)

FIG 41 PREVALENCE OF ALLERGIC DISEASES IN FRANCE, BY TYPE (2014–2030)

FIG 42 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY GENDER TYPE (2014–2030)

FIG 43 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY AGE-GROUP (2014–2030)

FIG 44 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY SEVERITY TYPE (2014–2030)

FIG 45 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY CAUSATIVE ALLERGEN (2014–2030)

FIG 46 PREVALENCE OF FOOD ALLERGY IN ITALY, BY TYPE (2014–2030)

FIG 47 PREVALENCE OF POLLEN ALLERGY IN ITALY, BY TYPE (2014–2030)

FIG 48 PREVALENCE OF INSECT ALLERGY IN ITALY, BY TYPE (2014–2030)

FIG 49 PREVALENCE OF ALLERGIC DISEASES IN ITALY, BY TYPE (2014–2030)

FIG 50 PREVALENCE OF ALLERGIC DISEASES IN SPAIN, BY GENDER TYPE (2014–2030)

FIG 51 PREVALENCE OF ALLERGIC DISEASES IN SPAIN, BY AGE-GROUP (2014–2030)

FIG 52 PREVALENCE OF ALLERGIC DISEASES IN SPAIN, BY SEVERITY TYPE (2014–2030)

FIG 53 PREVALENCE OF ALLERGIC DISEASES IN SPAIN, BY CAUSATIVE ALLERGEN (2014–2030)

FIG 54 PREVALENCE OF FOOD ALLERGY IN SPAIN, BY TYPE (2014–2030)

FIG 55 PREVALENCE OF POLLEN ALLERGY IN SPAIN, BY TYPE (2014–2030)

FIG 56 PREVALENCE OF INSECT ALLERGY IN SPAIN, BY TYPE (2014–2030)

FIG 57 PREVALENCE OF ALLERGIC DISEASES IN SPAIN, BY TYPE (2014–2030)

FIG 58 PREVALENCE OF ALLERGIC DISEASES IN THE U.K., BY GENDER TYPE (2014–2030)

FIG 59 PREVALENCE OF ALLERGIC DISEASES IN THE U.K., BY AGE-GROUP (2014–2030)

FIG 60 PREVALENCE OF ALLERGIC DISEASES IN THE U.K., BY SEVERITY TYPE (2014–2030)

FIG 61 PREVALENCE OF ALLERGIC DISEASES BY CAUSATIVE ALLERGEN IN THE U.K. (2014–2030)

FIG 62 PREVALENCE OF FOOD ALLERGY IN THE U.K., BY TYPE (2014–2030)

FIG 63 PREVALENCE OF POLLEN ALLERGY IN THE U.K., BY TYPE (2014–2030)

FIG 64 PREVALENCE OF INSECT ALLERGY IN THE U.K., BY TYPE (2014–2030)

FIG 65 PREVALENCE OF ALLERGIC DISEASES IN THE U.K., BY TYPE (2014–2030)

FIG 66 PREVALENCE OF ALLERGIC DISEASES IN JAPAN, BY GENDER TYPE (2014–2030)

FIG 67 PREVALENCE OF ALLERGIC DISEASES IN JAPAN, BY AGE-GROUP (2014–2030)

FIG 68 PREVALENCE OF ALLERGIC DISEASES IN JAPAN, BY SEVERITY TYPE (2014–2030)

FIG 69 PREVALENCE OF ALLERGIC DISEASES IN JAPAN, BY CAUSATIVE ALLERGEN (2014–2030)

FIG 70 PREVALENCE OF FOOD ALLERGY IN JAPAN, BY TYPE (2014–2030)

FIG 71 PREVALENCE OF POLLEN ALLERGY IN JAPAN, BY TYPE (2014–2030)

FIG 72 PREVALENCE OF INSECT ALLERGY IN JAPAN, BY TYPE (2014–2030)

FIG 73 PREVALENCE OF ALLERGIC DISEASES IN JAPAN, BY TYPE (2014–2030)

FIG 74 ALLERGY IMMUNOTHERAPY MARKET IN 7MM, $M (2017–2030)

FIG 75 ALLERGY IMMUNOTHERAPY MARKET, BY CAUSATIVE ALLERGEN IN 7MM, $M (2017–2030)

FIG 76 ALLERGY IMMUNOTHERAPY MARKET, BY THERAPY TYPE IN 7MM, $M (2017–2030)

FIG 77 ALLERGY IMMUNOTHERAPY MARKET, BY DISEASE TYPE IN 7MM, $M (2017–2030)

FIG 78 ALLERGY IMMUNOTHERAPY MARKET, BY COURSE OF TREATMENT IN 7MM, $M (2017–2030)

FIG 79 ALLERGY IMMUNOTHERAPY MARKET SHARE SPLIT IN 7MM (2018)

FIG 80 DRUG DISCOVERY AND APPROVAL PROCESS (PRE-CLINICAL AND CLINICAL TRIALS STAGES)

FIG 81 DRUG APPROVAL PROCESS (NDA REVIEW AND POST-MARKETING STAGES)

FIG 82 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN EU

FIG 83 MARKETING AUTHORIZATION PROCEDURES IN EU

FIG 84 CENTRALIZED PROCEDURE FOR DRUG APPROVAL

FIG 85 MUTUAL RECOGNITION PROCEDURE FOR DRUG APPROVAL

FIG 86 DECENTRALIZED PROCEDURE FOR DRUG APPROVAL

FIG 87 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN JAPAN

FIG 88 MARKET SHARE OF LATE-STAGE IMMUNOTHERAPIES IN 2030

FIG 89 BRAND SHARE ANALYSIS OF ALK-ABELLÓ A/S

FIG 90 BRAND SHARE ANALYSIS OF XXXX

FIG 91 BRAND SHARE ANALYSIS OF XXXX

FIG 92 ALK-ABELLÓ A/S – REVENUE SPLIT BY PRODUCT LINE AND GEOGRAPHY (2018)

FIG 93 XXXX – REVENUE SPLIT BY PRODUCT TYPE AND GEOGRAPHY (2018)

FIG 94 XXXX – REVENUE SPLIT BY GEOGRAPHY (2018)

FIG 95 XXXX – REVENUE SPLIT BY GEOGRAPHY (2019)

FIG 96 F. HOFFMANN-LA ROCHE LTD. – REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2018)

FIG 97 XXXX – REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2018)

FIG 98 XXXX – REVENUE SPLIT BY MARKETED PRODUCT (2018)